GU Cancers 2021 | ARCHES trial: enzalutamide plus ADT for mHSPC

Arun Azad • 19 Feb 2021

GU Cancers 2021

Genitourinary Cancer Prostate Cancer Enzalutamide

ARCHES

Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, shares an update on the results of the Phase III ARCHES trial (NCT02677896) investigating the safety and efficacy of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study has reported a significant improvement in radiographic progression-free survival. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Dr Arun Azad, MBBS, PhD, FRACP, has participated in speaker bureaus with Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono and Bayer, has received honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm and Merck Sharpe Dome; has participated in scientific advisory boards with Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen and Noxopharm; has received reimbursement for travel and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar and Pfizer; and has received research funding from Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional) and Ipsen (institutional).